CERS Stock Analysis: Buy, Sell, or Hold?
CERS - Cerus Corp
$2.81
0.02 (0.72%)
â˛
5d:
-5.7%
30d:
-2.09%
90d:
+2.55%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When CERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CERS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CERS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CERS is currently trading at $2.81, which is considered fair relative to its 30-day fair value range of $2.47 to $3.11. From a valuation perspective, the stock is trading at a discount (Forward PE: -562.0) compared to its historical average (76.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CERS is in a strong uptrend. Immediate support is located at $2.29, while resistance sits at $3.08.
Market Sentiment: CERS scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.67 (+66.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CERS is in a strong uptrend. Immediate support is located at $2.29, while resistance sits at $3.08.
Market Sentiment: CERS scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.67 (+66.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.47 -
$3.11
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (24/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 66.1% below Wall St target ($4.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.47 -
$3.11
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.29
Resistance Level
$3.08
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-562.00
Wall Street Target
$4.67
(+66.1%)
Revenue Growth (YoY)
9.5%
Profit Margin
-3.1%
PE vs Historical
-562.0 vs 76.8
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 10:32 PM ET
Data refreshes hourly during market hours. Next update: 11:32 PM
Data refreshes hourly during market hours. Next update: 11:32 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin Dennis Green
SELL
127544 shares
2026-03-12
Richard J Benjamin
SELL
101740 shares
2026-03-12
Vivek K Jayaraman
SELL
165200 shares
2026-03-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 35 SELL |
